Cited by 1,949Cancer-related Molecular PathwaysSarcoma Diagnosis and TreatmentHeat shock proteins research

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., Vogelstein, B.·1992·Nature

Open this paper in CoChat — free account

Abstract

Despite extensive data linking mutations in the p53 gene to human tumorigenesis, little is known about the cellular regulators and mediators of p53 function. MDM2 is a strong candidate for one such cellular protein; the MDM2 gene was originally identified by virtue of its amplification in a spontaneously transformed derivative of mouse BALB/c cells and the MDM2 protein subsequently shown to bind to p53 in rat cells transfected with p53 genes. To determine whether MDM2 plays a role in human cancer, we have cloned the human MDM2 gene. Here we show that recombinant-derived human MDM2 protein binds human p53 in vitro, and we use MDM2 clones to localize the human MDM2 gene to chromosome 12q13-14. Because this chromosomal position appears to be altered in many sarcomas, we looked for changes in human MDM2 in such cancers. The gene was amplified in over a third of 47 sarcomas, including common bone and soft tissue forms. These results are consistent with the hypothesis that MDM2 binds to p53, and that amplification of MDM2 in sarcomas leads to escape from p53-regulated growth control. This mechanism of tumorigenesis parallels that for virally-induced tumours, in which viral oncogene products bind to and functionally inactivate p53.

Integrity signals

Registry

Crossref · 10.1038/358080a0

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
Feinberg, A. P., & Vogelstein, B. (1983) · Analytical Biochemistry · doi:10.1016/0003-2697(83)90418-9 · Cited by 24,512
Self-citation
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,524
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Self-citation
A simple and very efficient method for generating cDNA libraries
Gubler, U., & Hoffman, B. J. (1983) · Gene · doi:10.1016/0378-1119(83)90230-5 · Cited by 4,461
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Self-citation
How eukaryotic transcriptional activators work
Ptashne, M. (1988) · Nature · doi:10.1038/335683a0 · Cited by 1,828
Identification of a Chromosome 18q Gene that Is Altered in Colorectal Cancers
Fearon, E. R., Cho, K. R., Nigro, J. M., Kern, S. E., Simons, J. W., Ruppert, J. M., Hamilton, S. R., Preisinger, A. C., Thomas, G., Kinzler, K. W., et al. (1990) · Science · doi:10.1126/science.2294591 · Cited by 1,760
Self-citation
Rapid transfer of DNA from agarose gels to nylon membranes
Reed, K. C., & Mann, D. A. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.20.7207 · Cited by 1,731
Casein kinase 2: An ‘eminence grise’ in cellular regulation?
Pinna, L. A. (1990) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(90)90098-x · Cited by 920

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 4

Hinds, P. W. et al. Cell Growth Differ. 1, 571–580 (1990).
Momand, J., Zambetti, G. P., Olson, D. C., George, D. L. & Levine, A. J. Cell (in the press).
Meltzer, P. S. et al. Cell Growth Differ. 2, 495–501 (1991).
Vogelstein, B. et al. Cancer Res. 47, 4806–4813 (1987).

Sorted by citations

Items 601–700 of 999

Teratogen-induced eye defects mediated by p53-dependent apoptosis
Wubah, J. A., Ibrahim, M. M., Gao, X., Nguyen, D. N., Pisano, M. M., & Knudsen, T. B. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00422-0 · Cited by 69
Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway
Bang, S., Kaur, S., & Kurokawa, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010261 · Cited by 69
New insights into p53 functions through its target microRNAs
Liao, J.-M., Cao, B., Zhou, X. Y., & Lu, H. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju018 · Cited by 71
The long and the short of it: the MDM4 tail so far
Haupt, S., Mejía-Hernández, J. O., Vijayakumaran, R., Keam, S. P., & Haupt, Y. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz007 · Cited by 70
p53 is a transcriptional activator of the muscle-specific phosphoglycerate mutase gene and contributes in vivo to the control of its cardiac expression.
Ruiz‐Lozano, P., Hixon, M. L., Wagner, M. W., Flores, A. I., Ikawa, S., Baldwin, A. S., Chien, K. R., & Gualberto, A. (1999) · PubMed · Cited by 69
Overrepresentation of 1q21–23 and 12q13–21 in lipoma-like liposarcomas but not in benign lipomas: A comparative genomic hybridization study
Szymanska, J., Virolainen, M. J., Tarkkanen, M., Wiklund, T. A., Asko-Seljavaara, S. L., Tukiainen, E. J., Elomaa, I., BLOMQVIST, C. P., & Knuutila, S. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00436-0 · Cited by 69
A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis
Nelson, V., Davis, G. E., & Maxwell, S. A. (2001) · APOPTOSIS · doi:10.1023/a:1011392811628 · Cited by 69
Regulation of p53 and MDM2 Activity by MTBP
Brady, M., Vlatković, N., & Boyd, M. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.2.545-553.2005 · Cited by 69
No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer
Campbell, I., Eccles, D., & Choong, D. Y. H. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.09.003 · Cited by 69
Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents
Buolamwini, J. K., Addo, J. K., Kamath, S., Patil, S. A., Mason, M., & Ores, M. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332672 · Cited by 69
Prognostic Implications of p53 Overexpression in Supratentorial Astrocytic Tumors
Chozick, B. S., Pezzullo, J. C., Epstein, M. H., & Finch, P. W. (1994) · Neurosurgery · doi:10.1227/00006123-199411000-00005 · Cited by 68
Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase
Giono, L. E., Resnick‐Silverman, L., Carvajal, L. A., Clair, S. S., & Manfredi, J. J. (2017) · Oncogene · doi:10.1038/onc.2017.254 · Cited by 68
Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis
Carr, M. I., & Jones, S. N. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.75 · Cited by 71
Stabilization of the MDM2 Oncoprotein by Mutant p53
Peng, Y., Chen, L., Li, C., Lu, W., Agrawal, S., & Chen, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000781200 · Cited by 67
Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation.
Shaulian, E., Zauberman, A., Milner, J., Davies, E. A., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05940.x · Cited by 69
Comparative genomic hybridization as a tool to define two distinct chromosome 12‐derived amplification units in well‐differentiated liposarcomas
Suijkerbuijk, R. F., Weghuis, D. E. M. O., Berg, M. V. D., van Kessel, A. G., Pédeutour, F., Turc‐Carel, C., Forus, A., Myklebost, O., & Glier, C. (1994) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870090410 · Cited by 68
Mdm2 Gene Amplification in Gastric Cancer Correlation with Expression of Mdm2 Protein and p53 Alterations
Günther, T., Schneider‐Stock, R., Häckel, C., Kasper, H., Pross, M., Hackelsberger, A., Lippert, H., & Roessner, A. (2000) · Modern Pathology · doi:10.1038/modpathol.3880107 · Cited by 67
Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence
Luo, H., Yount, C. L., Lang, H., Yang, A., Riemer, E. C., Lyons, K., Vanek, K. N., Silvestri, G. A., Schulte, B. A., & Wang, G. Y. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.04.017 · Cited by 65
Triptolide Inhibits MDM2 and Induces Apoptosis in Acute Lymphoblastic Leukemia Cells through a p53-Independent Pathway
Huang, M. J., Zhang, H., Liu, T., Tian, D., Gu, L., & Zhou, M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0425 · Cited by 67
Evaluation of p53, PCNA, Ki‐67, MDM2 and AgNOR in oral peripheral and central giant cell lesions
Souza, P., Mesquita, R. A., & Gomez, R. S. (2000) · Oral Diseases · doi:10.1111/j.1601-0825.2000.tb00319.x · Cited by 68
The Current and Future Therapies for Human Osteosarcoma
Lamplot, J. D., Denduluri, S. K., Qin, J., Li, R., Liu, X., Zhang, H., Chen, X., Wang, N., Pratt, A., Shui, W., et al. (2013) · Current Cancer Therapy Reviews · doi:10.2174/1573394711309010006 · Cited by 67
A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma
Davies, A. J., Lee, A. M., Taylor, C., Clear, A. J., Goff, L. K., Iqbal, S., Heavens, D., Calaminici, M., Norton, A. J., Lister, T. A., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403802 · Cited by 68
Frequent Loss of 9p21 (p16INK4A) and Other Genomic Imbalances in Human Malignant Fibrous Histiocytoma
Simons, A., Schepens, M. T., Jeuken, J. W. M., Sprenger, S. H. E., van de Zande, G., Bjerkehagen, B., Forus, A., Weibolt, V., Molenaar, I., van den Berg, E., et al. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00178-8 · Cited by 67
Hsp90 Is Essential for Restoring Cellular Functions of Temperature-sensitive p53 Mutant Protein but Not for Stabilization and Activation of Wild-type p53
Müller, P., Češková, P., & Vojtesek, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m412767200 · Cited by 69
MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas
Walter, H., Radig, K., Ryś, J., Bosse, A., Kuhnen, C., Hoang‐Vu, C., Roessner, A., & Schneider‐Stock, R. (1998) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050211 · Cited by 67
MDM2 gene amplification in human breast cancer
Quesnel, B., Preudhomme, C., Fournier, J., Fenaux, P., & Peyrat, J. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90128-7 · Cited by 67
Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 72
Regulation of p53 Stability and Apoptosis by a ROR Agonist
Wang, Y., Solt, L. A., Kojetin, D. J., & Burris, T. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034921 · Cited by 65
HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function
Stefano, V. D., Blandino, G., Sacchi, A., Soddu, S., & D’Orazi, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207656 · Cited by 67
Activation of an MDM2-specific Caspase by p53 in the Absence of Apoptosis
Pochampally, R. R., Fodera, B., Chen, L., Lu, W., & Chen, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.21.15271 · Cited by 66
Heritability of cervical tumours
Magnusson, P. K. E., Lichtenstein, P., & Gyllensten, U. B. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001201)88:5 · Cited by 179
Regulation of the mdm2 Oncogene by Thyroid Hormone Receptor
Qi, J.-S., Yuan, Y., Desai-Yajnik, V., & Samuels, H. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.864 · Cited by 65
Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation
Henriksen, J. M., Ågesen, T. H., Mælandsmo, G. M., Lothe, R. A., Myklebost, O., & Forus, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206671 · Cited by 65
Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness
Olivos, D. J., & Mayo, L. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121982 · Cited by 67
Terphenyl‐Based Helical Mimetics That Disrupt the p53/HDM2 Interaction
Yin, H. H., Lee, G., Park, H. S., Payne, G. A., Rodriguez, J. M., Sebti, S. M., & Hamilton, A. D. (2005) · Angewandte Chemie · doi:10.1002/ange.200462316 · Cited by 67
Patterns of gene amplification in gastrointestinal stromal tumors (GIST)
Tornillo, L., Duchini, G., Carafa, V., Lugli, A., Dirnhofer, S., Vizio, D. D., Boscaino, A., Russo, R., Tapia, C., Schneider‐Stock, R., et al. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700284 · Cited by 65
Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor
Matsuda, Y., Kawata, S., Nagase, T., Maeda, Y., Yamasaki, E., Kiso, S., Ishiguro, H., & Matsuzawa, Y. (1994) · Cancer · doi:10.1002/1097-0142(19940101)73:1 · Cited by 28
Immunohistochemical expression of p53, MDM2, Ki‐67 and PCNA in central giant cell granuloma and giant cell tumor
Souza, P. E. A., Paim, J. F., Carvalhais, J. N., & Gomez, R. S. (1999) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.1999.tb01996.x · Cited by 66
Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations.
Matsushima, A. Y., Cesarman, E., Chadburn, A., & Knowles, D. M., II (1994) · PubMed Central · Cited by 65
p53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation
Bourdon, J., D’Errico, A., Paterlini-Bréchot, P., Grigioni, W., May, E., & Debuire, B. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90217-1 · Cited by 65
A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene.
Markowitz, S. D., Myeroff, L. L., Cooper, M. J., Traicoff, J. L., Kochera, M., Lutterbaugh, J., Swiriduk, M., & Willson, J. K. V. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117048 · Cited by 65
p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors
Li, B., Cheng, Q., Li, Z., & Chen, J. (2010) · Cell Cycle · doi:10.4161/cc.9.7.11255 · Cited by 64
p53 Determines Multidrug Sensitivity of Childhood Neuroblastoma
Xue, C., Haber, M., Flemming, C. L., Marshall, G. M., Lock, R. B., MacKenzie, K. L., Gurova, K. V., Norris, M. D., & Gudkov, A. V. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4345 · Cited by 64
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program
Carol, H., Reynolds, C. P., Kang, M. H., Keir, S. T., Maris, J. M., Gorlick, R. G., Kolb, E. A., Billups, C. A., Geier, B., Kurmasheva, R. T., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24235 · Cited by 64
The Many Faces of MDM2 Binding Partners
Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 66
Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations
Yu, Q., Li, Y., Mu, K., Li, Z., Meng, Q., Wu, X., Wang, Y., & Li, L. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-71 · Cited by 67
Therapeutics targeting Bcl-2 in hematological malignancies
Ruefli-Brasse, A. A., & Reed, J. C. (2017) · Biochemical Journal · doi:10.1042/bcj20170080 · Cited by 64
Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma.
Tos, A. P. D., Piccinin, S., Doglioni, C., Vukosavljevic, T., Mentzel, T., Boiocchi, M., & Fletcher, C. D. �. (1997) · Europe PMC (PubMed Central) · Cited by 64
Over‐expression of the MDM2 gene is found in some cases of haematological malignancies
Quesnel, B., Preudhomme, C., Oscier, D. G., Lepelley, P., Hooghe, M. C., Facon, T. T. F., Zandecki, M., & Fenaux, P. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb05044.x · Cited by 64
Clinical Significance of mdm2 and p53 Expression in Bladder Cancer
Shiina, H., Igawa, M., Shigeno, K., Yamasaki, Y., Urakami, S., Yoneda, T., Wada, Y., Honda, S., & Nagasaki, M. (1999) · Oncology · doi:10.1159/000011971 · Cited by 64
MUTATION OF CELL CYCLE REGULATORS AND THEIR IMPACT ON SUPERFICIAL BLADDER CANCER
Rabbani, F., & Cordon-Cardo, C. (2000) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70237-8 · Cited by 63
Expression of p53 in oral mucosal hyperplasia, dysplasia and squamous cell carcinoma
Kerdpon, D., Rich, A., & Reade, P. (1997) · Oral Diseases · doi:10.1111/j.1601-0825.1997.tb00018.x · Cited by 64
Response of heat shock element within the human HSP70 promoter to mutated p53 genes.
Tsutsumi‐Ishii, Y., Tadokoro, K., Hanaoka, F., & Tsuchida, N. (1995) · PubMed · Cited by 64
Nitric Oxide-Mediated Inhibition of Hdm2−p53 Binding
Schonhoff, C. M., Daou, M., Jones, S. N., Schiffer, C. A., & Ross, A. H. (2002) · Biochemistry · doi:10.1021/bi026262q · Cited by 63
MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis
Li, G. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl047 · Cited by 63
Nuclear Envelope Rupture Is Enhanced by Loss of p53 or Rb
Yang, Z., Maciejowski, J., & de Lange, T. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0084 · Cited by 66
Overexpression of p53 Protein in Cutaneous T Cell Lymphoma: Relationship to Large Cell Transformation and Disease Progression
Li, G., Chooback, L., Wolfe, J. T., Rook, A. H., Felix, C. A., Lessin, S. R., & Salhany, K. E. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00167.x · Cited by 63
A Role for Hsc70 in Regulating Nucleocytoplasmic Transport of a Temperature-sensitive p53 (p53Val-135)
Akakura, S., Yoshida, M., Yoneda, Y., & Horinouchi, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100200200 · Cited by 63
From Amplification to Gene in Thyroid Cancer: A High-Resolution Mapped Bacterial-Artificial-Chromosome Resource for Cancer Chromosome Aberrations Guides Gene Discovery after Comparative Genome Hybridization
Chen, X., Knauf, J. A., Gonsky, R., Wang, M., Lai, E., Chissoe, S. L., Fagin, J. A., & Korenberg, J. R. (1998) · The American Journal of Human Genetics · doi:10.1086/301973 · Cited by 63
Checkpoint genes in cancer
McDonald, E. R., & El‐Deiry, W. S. (2001) · Annals of Medicine · doi:10.3109/07853890109002066 · Cited by 64
Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas
Patterson, H., Gill, S., Fisher, C., Law, M. G., Jayatilake, H., Fletcher, C., Thomas, M., Grimer, R. J., Gusterson, B. A., & Cooper, C. S. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.207 · Cited by 63
Ensemble-based virtual screening reveals dual-inhibitors for the p53–MDM2/MDMX interactions
Barakat, K., Mane, J. Y., Friesen, D. E., & Tuszyński, J. A. (2009) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2009.12.003 · Cited by 61
Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL -Rearranged Acute Lymphoblastic Leukemia
Richmond, J., Carol, H., Evans, K., High, L. M., Mendomo, A., Robbins, A. K., Meyer, C., Venn, N. C., Marschalek, R., Henderson, M. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2300 · Cited by 61
Human MDM2 Isoforms Translated Differentially on Constitutive versus p53-Regulated Transcripts Have Distinct Functions in the p53/MDM2 and TSG101/MDM2 Feedback Control Loops
Cheng, T.-H., & Cohen, S. N. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00235-06 · Cited by 62
Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival
Toffoli, G., Biason, P., Russo, A. G., Mattia, E. D., Cecchin, E., Hattinger, C. M., Pasello, M., Alberghini, M., Ferrari, C., Scotlandi, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2249 · Cited by 61
A Single Recombinant Adenovirus Expressing p53 and p21-targeting Artificial microRNAs Efficiently Induces Apoptosis in Human Cancer Cells
Idogawa, M., Sasaki, Y., Suzuki, H., Mita, H., Imai, K., Shinomura, Y., & Tokino, T. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2396 · Cited by 62
Malignant peripheral nerve sheath tumours: high Ki67 labelling index is the significant prognostic indicator
Watanabe, T., Oda, Y., Tamiya, S., Kinukawa, N., Masuda, K., & Tsuneyoshi, M. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01176.x · Cited by 62
Control of Human PIRH2 Protein Stability
Logan, I. R., Sapountzi, V., Gaughan, L., Neal, D. E., & Robson, C. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312712200 · Cited by 62
Amplification of MDM2 Inhibits MyoD-Mediated Myogenesis
Fiddler, T. A., Smith, L. G., Tapscott, S. J., & Thayer, M. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.5048 · Cited by 62
p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer
Mendrysa, S. M., Ghassemifar, S., & Malek, R. A. (2011) · Genes & Cancer · doi:10.1177/1947601911409736 · Cited by 65
DNA ploidy pattern in human chronic liver diseases and hepatic nodular lesions. Flow cytometric analysis on echo-guided needle liver biopsy
Anti, M., Marra, G., Rapaccini, G. L., Rumi, C., Bussa, S., Fadda, G., Vecchio, F. M., Valenti, A., Percesepe, A., Pompili, M., et al. (1994) · Cancer · doi:10.1002/1097-0142(19940115)73:2 · Cited by 48
UNRAVELLING THE GENETIC BASIS OF SUSCEPTIBILITY TO MYCOBACTERIAL INFECTION
Levin, M., & Newport, M. J. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199701)181:1 · Cited by 6
Sarcomas of Bone
Anderson, M. E., Randall, R. L., Springfield, D. S., & Gebhardt, M. C. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00092-8 · Cited by 59
Dissociation of Erythema and p53 Protein Expression in Human Skin Following UVB Irradiation, and Induction of p53 Protein and mRNA Following Application of Skin Irritants
Healy, E., Reynolds, N. J., Smith, M. D., Campbell, C., Farr, P. M., & Rees, J. L. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12395637 · Cited by 62
Uterine Smooth Muscle Tumors
Layfield, L. J., Liu, K., Dodge, R. K., & Barsky, S. H. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0221-usmt · Cited by 61
G→A mutations in p53 and Ha‐ras genes in esophageal papillomas induced by N‐nitrosomethylbenzylamine in two strains of rats
Lozano, J.-C., Nakazawa, H., Cros, M., Carbral, R., & Yamasaki, H. (1994) · Molecular Carcinogenesis · doi:10.1002/mc.2940090107 · Cited by 61
p53 in life and death.
Shimamura, A., & Fisher, D. E. (1996) · PubMed · Cited by 61
Mdm2 in growth signaling and cancer
Levav-Cohen, Y., Haupt, S., & Haupt, Y. (2005) · Growth Factors · doi:10.1080/08977190500196218 · Cited by 60
E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis
Wolyniec, K., Shortt, J., de Stanchina, E., Levav-Cohen, Y., Alsheich-Bartok, O., Louria‐Hayon, I., Corneille, V., Kumar, B., Woods, S. J., Opat, S., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387647 · Cited by 62
Signaling events controlling the molecular response to genotoxic stress
Holbrook, N. J., Liu, Y., & Fornace, A. J. (1996) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-9088-5_18 · Cited by 60
Loss of heterozygosity on chromosome 17 and mutation of the p53 gene in retinoblastoma
Kato, M. V., Shimizu, T., Ishizaki, K., Kaneko, A., Yandell, D. W., Toguchida, J., & Sasaki, M. S. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04305-4 · Cited by 60
A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells
Piccoli, R., Gaetano, S. D., Lorenzo, C. D., Grauso, M., Monaco, C., Spalletti-Cernia, D., Laccetti, P., Činátl, J., Matoušek, J., & D’Alessio, G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.7768 · Cited by 60
Increased p53 Protein Does Not Correlate to p53 Gene Mutations in Microdissected Human Testicular Germ Cell Tumors
Schenkman, N. S., Sesterhenn, I. A., Washington, L., Tong, Y. A., Weghorst, C. M., Buzard, G. S., Srivastava, S. K., & Moul, J. W. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)67122-2 · Cited by 60
Protein Kinase CK1δ Phosphorylates Key Sites in the Acidic Domain of Murine Double-Minute Clone 2 Protein (MDM2) That Regulate p53 Turnover
Winter, M., Milne, D., Dias, S., Kulikov, R., Knippschild, U., Blattner, C., & Meek, D. (2004) · Biochemistry · doi:10.1021/bi0489255 · Cited by 60
TP53-independent Function of miR-34a via HDAC1 and p21CIP1/WAF1
Zhao, J. Y., Lammers, P., Torrance, C. J., & Bader, A. G. (2013) · Molecular Therapy · doi:10.1038/mt.2013.148 · Cited by 62
Illuminating p53 function in cancer with genetically engineered mouse models
Garcia, P. B., & Attardi, L. D. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2013.12.014 · Cited by 65
Clinical utility of anti-p53auto-antibody: Systematic review and focus on colorectal cancer
Suppiah, A. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i29.4651 · Cited by 62
Rap2b, a novel p53 target, regulates p53-mediated pro-survival function
Zhang, X., He, Y., Lee, K. H., Dubois, W., Li, Z., Wu, X., Kovalchuk, A. L., Zhang, W., & Huang, J. L. (2013) · Cell Cycle · doi:10.4161/cc.24364 · Cited by 59
p53 in cancer: A paradigm for modern management of cancer
Steele, R. J., & Lane, D. P. (2005) · The Surgeon · doi:10.1016/s1479-666x(05)80041-1 · Cited by 59
DNA damage, oncogenesis and the p53 tumour-suppressor gene
Lee, J. M., Abrahamson, J., & Bernstein, A. (1994) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(94)90267-4 · Cited by 59
Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies
Vita, F. D., Orditura, M., Galizia, G., Romano, C. P., Infusino, S., Auriemma, A., Lieto, E., & Catalano, G. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991115)86:10 · Cited by 93
Interleukin 1 beta converting enzyme-like proteases are essential for p53-mediated transcriptionally dependent apoptosis.
Sabbatini, P., Han, J., Chiou, S., Nicholson, D. W., & White, E. (1997) · PubMed · Cited by 59
Interactions Between Papillomavirus Proteins and Tumor Suppressor Gene Products
Vousden, K. H. (1994) · Advances in cancer research · doi:10.1016/s0065-230x(08)60833-7 · Cited by 59
Analysis of glioma cell lines for amplification and overexpression of MDM2
He, J., Reifenberger, G., Liu, L., Collins, V. P., & James, C. D. (1994) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870110205 · Cited by 56
The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival
Valentin-Vega, Y. A., Okano, H., & Lozano, G. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.109 · Cited by 58
A Switch in p53 Dynamics Marks Cells That Escape from DSB-Induced Cell Cycle Arrest
Tsabar, M., Mock, C. S., Venkatachalam, V., Reyes, J. S., Karhohs, K. W., Oliver, T. G., Regev, A., Jambhekar, A., & Lahav, G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107995 · Cited by 54
Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
Sarkar, S., Jülicher, K., Burger, M. S., Della-Valle, V., Larsen, C., Yeager, T. R., Grossman, T. B., Nickells, R. W., Protzel, C., Jarrard, D. F., et al. (2000) · PubMed · Cited by 58
Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin‐3 in gastric cancer cells
Endo, S., Yamato, K., Hirai, S., Moriwaki, T., Fukuda, K., Suzuki, H., Abei, M., Nakagawa, I., & Hyodo, I. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01821.x · Cited by 61
Small-Molecule MDM2-p53 Inhibitors: Recent Advances
Zhang, B., Golding, B. T., & Hardcastle, I. R. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.13 · Cited by 59
Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.
Miller, C. T., Aggarwal, S. A., Lin, T. K., Dagenais, S. L., Contreras, J. I., Orringer, M. B., Glover, T. W., Beer, D. G., & Lin, L. (2003) · PubMed · Cited by 58

Authors: Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B.
Affiliations: University of Michigan (US)
Johns Hopkins University (US)
University of Pennsylvania (US)
ORCID: Oliner, J. D.
Kinzler, K. W.
Meltzer, P. S.
George, D. L.
Vogelstein, B.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1992-07
Volume: 358
Issue: 6381
Pages: 80-83
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/358080a0
OpenAlex: W2091151265
Cited by: 1,949
References: 32
Citations by year: 2026: 14 · 2025: 22 · 2024: 23 · 2023: 27 · 2022: 25 · 2021: 36 · 2020: 37 · 2019: 32 · 2018: 20 · 2017: 37 · 2016: 52 · 2015: 46 · 2014: 63 · 2013: 46 · 2012: 58
FWCI: 52.87
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Deep Blue (University of Michigan) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: MDM2, p53, gene amplification, sarcoma, p53 binding, tumor suppressor inactivation, bone sarcoma, soft tissue sarcoma, viral oncogenes, carcinogenesis
MeSH terms: Amino Acid Sequence, Base Sequence, Chromosomes, Human, Pair 12, Cloning, Molecular, DNA, Gene Amplification, Humans, Molecular Sequence Data, Neoplasm Proteins, Neoplasms, Nuclear Proteins, Proto-Oncogene Proteins, RNA, Messenger, RNA, Neoplasm, Sequence Homology, Nucleic Acid, Gene Expression, Tumor Suppressor Protein p53, Sequence Alignment, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amplification of a gene encoding a p53-associated protein in human sarcomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks